Partner
Mike Morin, who serves as Latham’s General Counsel, is a nationally recognized first-chair trial lawyer who handles some of the highest-profile litigations in the country, particularly in the life sciences sector. Mike previously served as Global Chair of the IP Litigation Practice, Global Vice Chair of the Litigation & Trial Department, and Global Co-Chair of the Healthcare & Life Sciences Industry Group.
Mike represents leading companies — from startups to global leaders — in their most critical intellectual property matters, including multi billion-dollar cases involving the world’s best-selling drugs, medical devices, consumer products, and software products. He has led some of the highest-profile patent cases in the country, particularly in the life sciences arena.
From the start of any engagement, Mike focuses on understanding a client’s business and goals — both for a specific litigation and as part of a long-term strategy. He draws on superior cross-examination skills, courtroom presence, and ability to build strong rapport with judges to develop early game plans and then leads teams to execute in trial, at arbitration, or on appeal. He has developed an impressive track record of wins, and a roster of clients that he has successfully served for decades.
Complementing his trial and appellate work, Mike advises clients on their IP portfolios and strategies, assists with licensing and transactional issues, and counsels clients on legal positions, responsibilities, and risk management.
Mike is widely recognized as a preeminent trial lawyer.
Mike also devotes considerable time to pro bono activities, representing disabled veterans in civil matters and indigent defendants in criminal cases.
He is a faculty member of the Trial Advocacy College at the University of Virginia and led the working group on parallel district court and PTO proceedings for the Sedona Conference.
Mike’s representative experience includes serving as lead counsel for:
Co-author, “Commentary on Patent Litigation Best Practices: Parallel USPTO Proceedings Chapter (“Stage Two”),” The Sedona Conference Working Group Series (July 2017)
Two Latham litigation teams recognized for securing a rare preliminary injunction in biosimilar patent litigation for J&J’s Jassen and a first-round dismissal with prejudice of a securities class action on behalf of VinFast.
Firm named M&A Firm of the Year and Securities Litigation Firm of the Year.
Shortlist for top firm and individual awards includes M&A Firm of the Year and Corporate Attorney of the Year.